Kevin Deane, MD
Rheumatology · Aurora, CONPI 1639269210
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,070 of the $29,395 with a category attached, or 68.3%. 8 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 55.6% of the total. Reporting peaked in 2019 at $13,373 and has fallen 80.4% since, to $2,623 in 2025. Among rheumatology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 40 payments — averaging $734.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$16K
- Phadia AB$5K
- Inova Diagnostics, Inc.$4K
- Boehringer Ingelheim$2K
- Phadia GmbH$2K
- AstraZeneca$130
- plus $155 from 2 others
Across 29 payments — averaging $47,133 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$962K
- Boehringer Ingelheim International GmbH$291K
- Pfizer$89K
- Inova Diagnostics, Inc.$25K
What the payments were for
- Consulting fees$20,07068%
- Speaking & faculty fees$3,64312%
- Travel & lodging$4,36915%
- Food & beverage$1,3134%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 25 | $16,341 |
| Phadia AB | 2 | $4,543 |
| Inova Diagnostics, Inc. | 3 | $3,525 |
| Boehringer Ingelheim | 3 | $2,480 |
| Phadia GmbH | 4 | $2,221 |
| AstraZeneca | 1 | $130 |
| Janssen Research & Development, LLC | 1 | $95 |
| Johnson & Johnson | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORENCIA$6,196
How this compares
$29,395 in reported general payments places this provider in the 90th percentile of 108 rheumatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 18 | $150,397 |
| Enbrel SureclickEtanercept | 18 | $107,001 |
| HumiraAdalimumab | 13 | $88,550 |
| XeljanzTofacitinib Citrate | 17 | $79,471 |
| Hydroxychloroquine Sulfate | 31 | $1,387 |
| MethotrexateMethotrexate Sodium | 34 | $1,383 |
| Prednisone | 30 | $270 |
| Alendronate Sodium | 17 | $233 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Aurora
- Larry MorelandAurora$55K
- Sterling WestAurora$42K
- Vernon HolersAurora$12K
- Christopher StriebichAurora$7K
- James LevineGreeley$130K
- Aryeh FischerDenver$114K
- Adam BerlinbergDenver$94K
- David TheisColorado Springs$61K
- Rennie McCabeDenver$58K
- Barbara GoldsteinDenver$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.